Denmark· DK-28120222503
Zevalin
A ibritumomab tiuxetan 90y product containing ibritumomab tiuxetan, yttrium (90-y), registered in Denmark by Schering AG. The same ATC class is registered in 7 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Ibritumomab tiuxetan 90y is registered in 7 of 19 countries.
Countries holding a registration under ATC V10XX02 (ibritumomab tiuxetan 90y), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 5 of them publish a price we can compare per daily dose
Ibritumomab tiuxetan 90y · ATC V10XX02
7 / 19 countries
- Belgiumprice
- Denmark
- Finlandprice
- Ireland
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- IBRITUMOMAB TIUXETAN, Yttrium (90-Y)
- Manufacturer
- Schering AG
- Country
- Denmark (DK)
- ATC code
- V10XX02
- ATC class
- Ibritumomab tiuxetan 90Y
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28120222503
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
199 interactions on record for ibritumomab tiuxetan 90y.
Graded by severity as the source publishes them — 127 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ibritumomab tiuxetan 90y · interactions on record
199 records
- 127 severe
- 72 moderate
Most severe, free to view
- DicoumarolB01AA01severe
- WarfarinB01AA03severe
- HeparinB01AB01severe
- Antithrombin IIIB01AB02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under V10XX02
Ibritumomab tiuxetan 90y, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9391dbee-65f5-4fec-9199-95ef185d0701 GET /v1/drugs/9391dbee-65f5-4fec-9199-95ef185d0701?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "radiofarmaceutisk præparationssæt til infusion",
"source": "dkma",
"strength": "1,6 mg/ml",
"auth_role": "RAP",
"dk_drugid": "28120222503",
"substance": "IBRITUMOMAB TIUXETAN, Yttrium (90-Y)",
"auth_procedure": "Central",
"in_medicinpriser": true,
"registration_date_serial": "38002"
}See everything about ibritumomab tiuxetan 90y.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.